Capricor Therapeutics, Inc. (CAPR) Financial Analysis & Valuation | Quarter Chart
Capricor Therapeutics, Inc. (CAPR)
CAPRPrice: $26.13
Fair Value: 🔒
🔒score
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, whic... more
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of t... more
Description
Shares
| Market Cap | $1.19B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Linda Marbán |
| IPO Date | 2007-02-13 | CAGR | — |
| Employees | 160 | Website | www.capricor.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CAPR chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.34B | P/E Ratio | -14.93 |
| Forward P/E | -83.18 | PEG Ratio | — |
| P/S Ratio | 80669975222463888 | P/B Ratio | 9994612881771988 |
| P/CF Ratio | -20593283513523568 | P/FCF Ratio | -19047813722892512 |
| EPS | $-1.75 | EPS Growth 1Y | 69.03% |
| EPS Growth 3Y | 60.71% | EPS Growth 5Y | 68.22% |
| Revenue Growth 1Y | -52.08% | Gross Margin | 0.88% |
| Operating Margin | -5.48% | Profit Margin | -5.22% |
| ROE | -0.63% | ROA | -0.52% |
| ROCE | -0.7% | Current Ratio | 4.37 |
| Quick Ratio | 4.37 | Cash Ratio | 0.82 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 21.92 | Piotroski Score | 2 |